A year ago, they were trading at $3.16. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX
The decrease was primarily driven by first quarter cash used in operating activities of approximately $28.0 million and partially offset by the receipt of $11.7 million from sales of common stock under our Cantor agreement. At March 31, …
Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice …
What's behind this double-digit move lower? Celldex's shares appear to have gotten caught up in the marketwide downturn last month. The biotech, after all, didn't release any material news to speak of during the course of February. Celldex …
March has been a good month so far for Celldex Therapeutics (NASDAQ: CLDX) shareholders. The stock is up more than 20% this month, including a big jump last week that stemmed primarily from investor anticipation of the release of …